药物治疗对强迫症患者行为抑制/激活系统的影响研究
Study on the effects of drug treatment on the behavioral inhibition/activation systems in patients with obsessive-compulsive disorder

目的 ·研究药物治疗对强迫症（OCD）患者行为抑制/激活系统的影响。方法 ·以 35例OCD患者与35例健康对照为研究对象。采用耶鲁-布朗强迫量表、行为激活/行为抑制系统量表进行基线评估；对OCD患者进行3个月药物治疗，并在药物治疗之后再次采用耶鲁-布朗强迫量表、行为抑制/激活系统量表进行随访评估。比较OCD组与对照组、药物治疗前后、不同疗效组之间行为抑制/激活系统的差异。结果 ·OCD患者的反应抑制系统与健康对照存在显著差异（F=34.255，P=0.000），且在药物治疗前后，OCD患者的反应抑制系统也存在显著差异（t=-2.302，P=0.028）。药物治疗前后，在控制了基线耶鲁-布朗强迫量表分数后，不同疗效组（临床治愈、有效、无效）在行为激活–愉悦追求的主效应均显著（F=4.868，P=0.035），在反应抑制系统上疗效的主效应均显著（F=4.500，P=0.019）。结论 · OCD患者行为抑制系统的活跃性较健康对照差；随着OCD症状治愈程度的改变，其抑制功能也发生改变；治疗前后不同疗效组行为激活–愉悦追求存在显著差异。
： Objective · To investigate the effects of drug treatment on the behavioral inhibition system (BIS) and behavioral activation system (BAS) in patients with obsessive-compulsive disorder (OCD). Methods · A total of 35 patients with OCD and 35 healthy controls were enrolled. The Yale-Browan obsessive compulsive scale (YBOCS) and behavioral inhibition system and behavioral activation system scale (BIS/BAS) were used for baseline assessment. OCD patients received drug treatment for three months. Then YBOCS and BIS/BAS were used again for follow-up assessment. The differences in BIS and BAS between the OCD and control groups, before and after drug treatment, and different efficacy groups were compared. Results · The BIS in the OCD group was significantly different from that in the control group (F=34.255, P=0.000). There was a significant difference in BIS before and after drug treatment (t=-2.302, P=0.028). Also there was a significant difference in the main effect of behavioral activation system scale-fun seeking (BASF) between different efficacy groups when controlling the basic YBOCS score before and after drug treatment (F=4.868, P=0.035). The main effect of efficacy on the BIS was significant (F=4.500, P=0.019). Conclusion · The activity of BIS in OCD patients was poorer than that of healthy controls. With the change of severity of OCD symptoms, the inhibition function of OCD changed as well. There was a significant difference in the BASF in different efficacy groups before and after drug treatment